Account
Insider Insights
05.05.2023
HAS issues favorable reimbursement opinion

This is the first time that HAS is issuing a favorable opinion for the reimbursement of a technology...

Read more
Articles
13.04.2023
What are Joint Scientific Consultations and why th...

We explore joint scientific consultations; what they mean and why they are important to manufacturer...

Read more
Insider Insights
14.03.2023
Newly agreed Windsor Framework carries significant...

Windsor Framework replaces the Northern Ireland protocol to address issues and provide significant c...

Read more
Articles
22.02.2023
What are the risks and benefits of Early Access Pr...

Using Early Access Programs (EAPs) to give patients with life threatening conditions access to medic...

Read more
Articles
15.02.2023
What early access opportunities exist for innovati...

Our Market Access experts investigate what early access opportunities are available in China to enab...

Read more
Articles
08.02.2023
Which countries fund early access and why don’t ...

The provision of funding for Early Access Programmes is not ubiquitous. We explore which EU5 countri...

Read more
Case Study
27.01.2023
Payer value proposition development

Payer value proposition development and understanding evidence requirements to secure pricing and re...

Read more
Articles
26.01.2023
What have we learned from the UK EAMS process?

Almost a decade after it's inception, what have we learned from the UK early access to medicines sch...

Read more
Insider Insights
25.01.2023
UK to introduce first-of-its-kind framework to aid...

MHRA announces UK will introduce new framework aimed at making the manufacture of innovative medicin...

Read more
Newsletter
15.12.2022
PMA Insights: Week 50

We summarise four handpicked articles from pharmaceutical, pricing and market access that are worth ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.